HRJR7T.jpg

Harnessing The Power of
NK Cells to Defeat Cancer

 
Screen%20Shot%202020-06-17%20at%203.05_edited.jpg

News & Events

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer

June 3rd, 2020

CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2
(COVID-19)

April 7th, 2020

Cytovia CEO Dr. Daniel Teper Featured on MSQ Webinar Series

March 24th, 2020

Hebrew University to Collaborate with Cytovia Therapeutics on Natural Killer Cell Research

March 18th, 2020

Webcast: BIO CEO & Investor Conference

February 12th, 2020

Cytovia CEO interviewed by Proactive

February 11th, 2020

 
Screen Shot 2020-06-17 at 3.05.08 PM.png

News & Events

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer

June 3rd, 2020

CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2
(COVID-19)

April 7th, 2020

Cytovia CEO Dr. Daniel Teper Featured on MSQ Webinar Series

March 24th, 2020

Hebrew University to Collaborate with Cytovia Therapeutics on Natural Killer Cell Research

March 18th, 2020

Webcast: BIO CEO & Investor Conference

February 12th, 2020

Cytovia CEO interviewed by Proactive

February 11th, 2020

 
Screen Shot 2020-06-09 at 3.17.30 PM.png

News & Events

 

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer

June 3rd, 2020

CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2
(COVID-19)

April 7th, 2020

Cytovia CEO Dr. Daniel Teper Featured on MSQ Webinar Series

March 24th, 2020

Screen%20Shot%202020-06-09%20at%203.35_edited.jpg

News & Events

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer

June 3rd, 2020

CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2
(COVID-19)

April 7th, 2020

Cytovia CEO Dr. Daniel Teper Featured on MSQ Webinar Series

March 24th, 2020

Hebrew University to Collaborate with Cytovia Therapeutics on Natural Killer Cell Research

March 18th, 2020

Webcast: BIO CEO & Investor Conference

February 12th, 2020

Cytovia CEO interviewed by Proactive

February 11th, 2020

 
Screen Shot 2020-06-30 at 3.03.02 PM.png

News & Events

 

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer

June 3rd, 2020

CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2
(COVID-19)

April 7th, 2020

Cytovia CEO Dr. Daniel Teper Featured on MSQ Webinar Series

March 24th, 2020

video camera conference

News & Events

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer

June 3rd, 2020

CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2
(COVID-19)

April 7th, 2020

Cytovia CEO Dr. Daniel Teper Featured on MSQ Webinar Series

March 24th, 2020

Hebrew University to Collaborate with Cytovia Therapeutics on Natural Killer Cell Research

March 18th, 2020

Webcast: BIO CEO & Investor Conference

February 12th, 2020

Cytovia CEO interviewed by Proactive

February 11th, 2020

 

News & Events

 

Cytovia Therapeutics Wins Top Industry Award

March 1, 2025

Subscribe Form

  • Facebook
  • Twitter
  • LinkedIn
  • YouTube